Table 4.
Subgroup | Adjuvant chemotherapy | No adjuvant chemotherapy | RFS | OS | ||
---|---|---|---|---|---|---|
|
|
|||||
HR (95% CI) | p value | HR (95% CI) | p value | |||
Visceral pleural involvement (n = 258) | 122 | 136 | 0.450 (0.241–0.841) | 0.012 | 0.146 (0.045–0.471) | 0.001 |
| ||||||
Adenocarcinoma (n = 237) | 107 | 130 | 0.390 (0.196–0.776) | 0.007 | 0.079 (0.011–0.590) | 0.013 |
| ||||||
Tumor size ≤ 3 cm (n = 204) | 98 | 106 | 0.453 (0.214–0.959) | 0.039 | 0.135 (0.032–0.568) | 0.006 |
| ||||||
Visceral pleural involvement and tumor size ≤ 3 cm (n = 203) | 98 | 105 | 0.453 (0.214–0.958) | 0.038 | 0.135 (0.032–0.567) | 0.006 |
The multivariate analysis was conducted using a backward elimination procedure for variables with p < 0.2 in the univariate analysis. In univariate analysis, adjuvant chemotherapy, age, sex, histology, tumor diameter, smoking history, and high-risk factors were analyzed.
RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.